Table 6.

Adverse events occurring in ≥10% of patients treated with a first-line BCR-ABL1 TKI.^1–3

	Dasatinib2 100 mg QDa (n = 258)		Imatinib1 400 mg QDb (n = 551)		Nilotinib3 300 mg BIDc (n = 279)
	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4
Nonhematologic AE
Abdominal pain	11	0	37	4	15	2
Constipation	NR	NR	11	1	20	<1
Cough	NR	NR	20	<1	17	0
Diarrhea	22	1	45	3	19	1
Dizziness	NR	NR	19	1	12	<1
Dyspepsia	NR	NR	19	0	10	0
Fatigue	11	<1	39	2	23	1
Fluid retention	38	5	62	3	NR	4
Headache	14	0	37	1	32	3
Influenza	NR	NR	14	<1	13	0
Insomnia	NR	NR	15	0	11	0
Arthralgia/joint pain	7	0	31	3	22	<1
Myalgia	7	0	24	2	19	<1
Nasopharyngitis	NR	NR	31	0	27	0
Nausea	10	0	50	1	22	2
Pyrexia	NR	NR	18	1	14	<1
Rash and related termsd	14	0	40	3	38	<1
Upper respiratory tract infection	NR	NR	21	<1	17	<1
Vomiting	5	0	23	2	15	<1
Hematologic AE
Neutropenia		29		17		12
Thrombocytopenia		22		9		10
Anemia		13		4		4

AE: adverse event; BID: twice daily; NR: not reported in ≥10% of patients; QD: once daily; TKI: tyrosine kinase inhibitor.

^aMinimum of 60 months follow-up.²

^bStudy versus interferon-α.¹

^c60-month analysis.³

^dIncludes erythema, erythema multiforme, rash, rash generalized, rash macular, rash papular, rash pustular, skin exfoliation, and rash vesicular.